CTRI/2009/091/000145Other3 期
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK-0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA, in Treatment-Naïve HIV Infected Patients
Merck Sharp and Dohme0 个研究点目标入组 750 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- Other
- 发起方
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patient is male or female 18 years of age or older
- •Patient is HIV positive
- •Patient is naïve to antiretroviral therapy (ART) or has received less than 7 days total of any ART
排除标准
- •Patient is a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence
- •Patient has documented resistance to tenofovir or emtricitabine
- •Patient is currently participating or has participated in a study with an investigational compound or device within 45 days of signing informed consent
- •Patient is pregnant or breastfeeding, or expecting to conceive
研究者
相似试验
进行中（未招募）
1 期
MK-0431A XR in Pediatric Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on MetformiType 2 Diabetes MellitusEUCTR2012-004035-23-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as240
进行中（未招募）
1 期
MK-1439A once a day versus ATRIPLA once a day in treatment-naïve HIV-1 infected subjectsHuman Immunodeficiency Virus-1 infectionMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2014-003382-17-PTMerck Sharp & Dohme LLC680
已完成
不适用
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Each in Combination With TRUVADA™, in Treatment-Naïve HIV-1 Infected Subjects-B20 Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseasesHuman immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseasesB20PER-031-14MERCK SHARP & DOHME PERU S.R.L.,8
进行中（未招募）
不适用
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK-0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients - Safety and efficacy of once daily raltegravir compared to twice daily raltegravirHIV infectionMedDRA version: 11Level: PTClassification code 10020161Term: <Manually entered code. Term in E.1.1>EUCTR2008-002733-70-NLMSD BV750
进行中（未招募）
1 期
Reformulated raltegravir (1200 mg) once a day versus raltegravir (400mg) twice a day in treatment-naïve patientsHuman immunodeficiency virus infectionMedDRA version: 16.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-001939-47-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.750